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Europe and South America. Baseline demographics and lesion characteristics were
evenly distributed. No acute, subacute or late thrombosis occurred. The two-years results
are shown below 
Conclusion: The QCA data demonstrate virtually no neointimal in-stent proliferation and
very little TLR and TVR within the Sirolimus group, and with event-free survival of 90% at
two years. Three-year clinical follow-up data will be presented.
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1155-77 Clinical, Angiographic, and Intravascular Ultrasound 
Comparisons Between Patients With Early Versus Late 
Saphenous Vein Graft Failure
Daniel Arthur Canos, Gary S. Mintz, Jose R. Cordero, Esteban Escolar, Jun-Ichi Kotani, 
Natalie Gevorkian, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Neil J. 
Weissman, Medstar Research Institute, Washington, DC
Background: Up to 20% of saphenous vein grafts (SVG) fail in the 1st yr. The etiology of
early failure is not well understood. Methods: We used coronary angiography and intra-
vascular ultrasound (IVUS) to analyze 100 pts (121 lesions) with early (<1 yr) SVG failure
and 200 pts (289 lesions) with late (>1yr) SVG failure. IVUS assessment included refer-
ence and lesion SVG, lumen, and plaque areas; plaque burden (SVG/plaque area);
remodeling (lesion/reference SVG area); and morphology.
Results: Risk factors were identical in both groups: smoking (44%), diabetes (36%),
hypercholesterolemia (70%), and hypertension (63% early vs 72% late, p = 0.14). Early
failure pts had more anginal rest pain (34.3% vs.19.8%). Comparing early to late failure,
lesion location was proximal in 62% vs 42% (ostial in 37% vs 18%), mid-segment in 13%
vs 29%, distal in 13% vs 20%, and distal anastomosis in 13% vs 5%. Lesion length was
similar (9.6 vs 9.27 mm, p= 0.7). The early failure group had smaller references (IVUS
and angio: 2.74± 0.86 vs 3.26± 0.83 mm, p< 0.01) and little remodeling at the lesion site.
Conversely, late failure lesions had significantly less reference segment plaque burden,
but more mobile plaque elements (21.4% vs 0%, p= 0.01) and calcific plaque (17.9 % vs.
0%, p= 0.02).
Conclusion: Early SVG failure occurs more often at the ostium. Grafts failing <1yr have
more reference segment plaque and less lesion site remodeling suggesting a more
aggressive disease process with intrinsic graft fibrosis. 
1155-78 Implications and Prevention of Large Periprocedural 
Myocardial Infarction After Percutaneous Intervention 
of Diseased Saphenous Vein Grafts and Thrombotic 
Native Coronary Lesions
Zoran Lasic, Roxana Mehran, Eugenia Nikolsky, Manuela Negoita, Ricardo Costa, David 
A. Cox, Joseph Babb, Dean Nukta, Luc Bilodeau, Louis Cannon, Thomas D. Stuckey, 
James Hermiller, Alexandra Lansky, Martin B. Leon, Gregg W. Stone, Lenox Hill Hospital, 
New York City, NY
Background: Peri-procedural myonecrosis after percutaneous coronary intervention
(PCI) is especially common after intervention in saphenous vein grafts (SVG) and throm-
botic lesions, and is strongly associated with worse short and long-term outcomes, espe-
cially when the CPK-MB is >8x normal or Q-wave MI develops. Whether thrombectomy
can decrease the incidence of large peri-procedural myocardial infarctions and improve
outcomes in these high risk situations is unknown.
Methods: We analyzed the effectiveness of thrombectomy with the ev3 X-SIZER in pre-
venting large peri-procedural MIs (Q-wave or CK-MB >8x nl) in the multicenter prospec-
tive X-TRACT trial, in which 797 pts undergoing PCI of diseased SVGs and thrombus
containing native coronary arteries were randomized to thrombectomy vs. control prior to
stenting.
Results: Baseline clinical and demographic data were similar in both groups. Definite
thrombus was present in 191 (47.8%) X-SIZER patients and 164 (41.3%) of control
patients (p<0.07). A total of 60 patients (7.5%) developed a large MI within 30-days after
PCI, including 22 (2.7%) in X-SIZER group and 38 (4.7%) in control group, p<0.03. Large
MI within 30-days after PCI occurred in 10.1% of pts with definite thrombus vs. 5.4% of
pts without definite thrombus (p<0.01). Among pts with thrombus, X-SIZER use
decreased the occurrence of large MI from 14% to 6.8%, p<0.03. The 30-day rate of
repeat target vessel revascularization was increased in pts with vs. without large MI
(8.3% vs. 1.1%, p=0.001). Six-month mortality occurred in 5.0% of patients with CK-MB
>8x normal, compared to 2.4% of pts without CPK-MB >8x normal (p=0.193).
Conclusion: Large peri-procedural myocardial infarctions after intervention in diseased
SVGs and thrombus containing native coronary arteries is associated with an increased
need for early target revascularization, and a trend for increased late mortality. Throm-
bectomy with the X-SIZER prior to stent implantation in these high risk lesions reduces
the occurrence of large peri-procedural myocardial infarctions. Larger studies are
required to demonstrate whether this directly results in a survival advantage with throm-
bectomy.
1155-79 Drug-Eluting Balloon: A New Technique to Deliver 
Paclitaxel to the Angioplasty Site
Kai Hogrefe, Kamal Chitkara, Anthony H. Gershlick, University of Leicester, Leicester, 
United Kingdom
Background:
Paclitaxel, which stabilizes microtubules and renders the affected cell incapable of prolif-
eration and migration, has been shown to reduce neointimal formation. Paclitaxel-loaded
stents have been successfully used in the clinical setting to deliver this very potent agent
to the vessel wall. There are, however, situations such as in- or persistent restenosis or
small vessel angioplasty when a drug eluting stent might not be ideal because of the
thrombosis risk or when their use is inappropriate (edge residual stenosis). In this exper-
iment we loaded paclitaxel onto conventional angioplasty balloon and delivered it to
human arterial wall ex vivo.
Methods:
Whole angioplasty balloons were inflated and then loaded with paclitaxel by immersing
(for 1 hour) into paclitaxel solution (10 mg/ml and 20 mg/ml) spiked with radiolabelled-
paclitaxel. After air-drying, the balloons were placed in scintillation fluid and beta-
counted. Elution of loaded paclitaxel was measured in buffer and blood for up to 10 min.
Paclitaxel loaded balloons were placed inside fresh internal mammary arteries (IMA)
segment, incubated at 37°C and were inflated at 8 atmospheric pressure for 1 and 10
minutes. Intramural deposition was measured after flushing the vessel segment with 5
mls of blood.
Results:
Paclitaxel was loaded successfully onto conventional angioplasty balloon of various
sizes. Corrected for balloon surface area, we achieved paclitaxel loading of 0.22 µg/mm²
after immersion in 10mg/ml paclitaxel solution and 0.37 µg/mm² in 20 mg/ml (p=0.005).
There was little paclitaxel elution in blood and in buffer in the first 10 min (6.2% and 9.7%
respectively). Further, 34.8% paclitaxel was deposited in the artery wall after 1 minute
and 36.7% after 10 minute balloon inflation.
Conclusion:
Paclitaxel can be successfully loaded onto an angioplasty balloon. There was minimal
loss of paclitaxel into blood and up to 34.8% delivery efficiency into internal mammary
artery after 1 minute balloon inflation. Further studies with this novel drug eluting balloon
(DEB) are ongoing to evaluate its effect on smooth muscle cell proliferation in vitro and
restenosis in vivo. Restenosis after balloon angioplasty alone may be reduced.
1155-80 Morbidity and Mortality Associated With Retroperitoneal 
Bleeding Following Percutaneous Coronary 
Intervention With Femoral Artery Access
Charles L. Laham, Mayo Clinic, Rochester, MN
Background: Little is known of the clinical sequelae of retroperitoneal bleeding (RPB) fol-
lowing a femoral access percutaneous coronary intervention (PCI).
Methods and Results: We analyzed the Mayo PCI database and identified 55 patients
(pts) with RPB between 12/01/93 and 6/30/02. We matched 4 pts (controls) without RPB
(total n=220) for each RPB pt based on gender, age within 5 years and PCI within 1 year.
Adverse events in-hospital and at 6 months were analyzed. Among RPB pts, PCI was
Sirolimus Control P-value
Reference diameter (mm) 2.60 2.64 NS
MLD Post-procedure (mm) 2.43 2.41 NS
MLD Follow-up (mm) – 6 month 2.42 1.64 .0001
Late loss (mm) 0.01 0.80 .0001
Restenosis rate (%) 0.0 26.1 .0001
TLR-free – 2 years 97.4 86.2 .0001
TVR-free – 2 years 96.6 83.6 .0001
TVF-free – 2 years 94.1 78.7 .0001
MACE-free – 2 years 90.0 80.5 .0001
IVUS
Characteristics
Early Failure (<1yr) Late Failure (>1yr) p
Distal SVG Area mm2 14.2 ± 7.9 14.6 ± 7.9 0.84
Lumen Area mm2 6.8 ± 5.2 9.9 ± 4.9 0.03
Plaque Burden % 52 ± 17 34 ± 12 <0.01
Proximal SVG Area mm2 14.0 ± 9.5 18.8 ± 7.2 0.08
Lumen Area mm2 6.8 ± 7.9 11.4 ± 4.5 0.02
Plaque Burden 54 ± 19 38 ± 12 0.02
Lesion SVG Area mm2 13.7 ± 7.3 16.8 ± 4.8 0.07
Lumen Area mm2 2.1 ± 1.2 5.0 ± 3.5 < 0.01
Remodeling 0.97 ± 0.23 1.07 ± 0.21 0.09
